Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Hansoh Pharmaceutical Group Company Ltd
Interest Income Expense
Hansoh Pharmaceutical Group Company Ltd
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Interest Income Expense
¥54.6m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Interest Income Expense
¥145.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
23%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Interest Income Expense
¥472.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
21%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Interest Income Expense
¥958.5m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Interest Income Expense
¥65.5m
|
CAGR 3-Years
41%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Interest Income Expense
-¥20.1m
|
CAGR 3-Years
-107%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hansoh Pharmaceutical Group Company Ltd
Glance View
Nestled in the heart of China's burgeoning pharmaceutical industry, Hansoh Pharmaceutical Group Company Ltd. stands as a beacon of innovation and resilience. Founded in 1995, Hansoh has carved a niche for itself by focusing on the development, manufacturing, and distribution of a diverse portfolio of drugs. The company has garnered attention by zeroing in on therapeutic areas such as oncology, central nervous system disorders, anti-infectives, and diabetes, aiming to address the pressing needs of a growing patient population. This targeted strategy has not only positioned Hansoh as a formidable player in China's pharmaceutical landscape but also allowed it to compete on a global scale through its commitment to high-quality and affordable healthcare solutions. Hansoh's business model revolves around two core components: research and development (R&D) and strategic distribution. The company has invested heavily in R&D, maintaining an extensive pipeline of innovative drugs that promise to bolster its revenue streams. By focusing on a mix of generic and proprietary medications, Hansoh capitalizes on both established market demands and emerging medical needs. Additionally, its robust distribution network ensures that its products reach a broad array of hospitals and pharmacies, both within China and beyond. This dual approach of scientific advancement paired with efficient delivery mechanisms underpins Hansoh's business success, allowing it to generate steady revenues while paving the way for future growth in international markets.
See Also
What is Hansoh Pharmaceutical Group Company Ltd's Interest Income Expense?
Interest Income Expense
54.6m
CNY
Based on the financial report for Dec 31, 2024, Hansoh Pharmaceutical Group Company Ltd's Interest Income Expense amounts to 54.6m CNY.
What is Hansoh Pharmaceutical Group Company Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-24%
Over the last year, the Interest Income Expense growth was -95%. The average annual Interest Income Expense growth rates for Hansoh Pharmaceutical Group Company Ltd have been -45% over the past three years , -24% over the past five years .
You don't have any saved screeners yet